Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF). In breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Roberto J., Petry, Vanessa, Hoff, Paulo M., Mano, Max S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001168/
https://www.ncbi.nlm.nih.gov/pubmed/29946467
http://dx.doi.org/10.1186/s40364-018-0135-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001168/
https://www.ncbi.nlm.nih.gov/pubmed/29946467
http://dx.doi.org/10.1186/s40364-018-0135-x

Ejemplares similares